Ypsomed Overview
- Year Founded
-
1984
- Status
-
Public
- Employees
-
2,099
- Stock Symbol
-
YPSN
- Investments
-
6
- Share Price
-
$514.79
- (As of Friday Closing)
Ypsomed General Information
Description
Ypsomed, based in Burgdorf, Switzerland, develops and manufactures self-injection devices like pens, autoinjectors, and infusion systems for global pharma and biotech companies. The company shifted focus to business-to-business injection systems, divesting its diabetes care segment to supply device platforms to pharma partners.The company operates in a market driven by strong growth in biologics, biosimilars, patient self-administration, and GLP-1 therapies for obesity. To meet demand, Ypsomed has embarked on an ambitious capacity expansion program, with capital expenditure reaching approximately 50% of sales in recent years. This investment is partially derisked through customer co-financing, which aligns incentives and secures future volume commitments before launch.
Contact Information
Website
www.ypsomed.comCorporate Office
- Brunnmattstrasse 6
- 3401 Burgdorf
- Switzerland
Corporate Office
- Brunnmattstrasse 6
- 3401 Burgdorf
- Switzerland
Ypsomed Stock Performance
As of 13-Nov-2026, Ypsomed’s stock price is $514.79. Its current market cap is $6.77B with 13.1M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $514.79 | $525.24 | $338.46 - $525.48 | $6.77B | 13.1M | 15.5K | $15.84 |
Ypsomed Financials Summary
As of 30-Sep-2026, Ypsomed has a trailing 12-month revenue of $861M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2026 31-Mar-2026 | FY 2025 31-Mar-2025 | FY 2024 31-Mar-2024 |
|---|---|---|---|---|
| EV | 6,045,635 | 4,799,915 | 5,569,828 | 5,616,951 |
| Revenue | 860,876 | 910,847 | 844,373 | 619,040 |
| EBITDA | 362,686 | 405,878 | 215,127 | 182,171 |
| Net Income | 211,305 | 276,534 | 98,664 | 88,451 |
| Total Assets | 1,784,070 | 1,683,246 | 1,510,052 | 1,212,114 |
| Total Debt | 404,292 | 325,961 | 416,577 | 283,726 |
Ypsomed Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Ypsomed Comparisons
Industry
Financing
Details
Ypsomed Competitors (4)
One of Ypsomed’s 4 competitors is West Pharmaceutical Services, a Corporation company based in Exton, PA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| West Pharmaceutical Services | Corporation | Exton, PA | ||||
| Nemera | Private Equity-Backed | Lyon, France | ||||
| SteriPack Group | Private Equity-Backed | Bristol, United Kingdom | ||||
| SHL Medical | Private Equity-Backed | Zug, Switzerland |
Ypsomed Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Ypsomed Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Ypsomed Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Ypsomed Investments & Acquisitions (6)
Ypsomed’s most recent deal was a Grant with Visienco for . The deal was made on 23-Jan-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Visienco | 23-Jan-2026 | Grant | Discovery Tools (Healthcare) | ||
| Crescent Communities (Building H of the Yield in Holly Springs, North Carolina) | 20-Nov-2025 | Corporate Asset Purchase | Buildings and Property | ||
| CeQur Simplicity | 13-Apr-2021 | Later Stage VC | Therapeutic Devices | ||
| ICU Medical (Diabetes Infusion Set Business) | 03-Nov-2011 | Merger/Acquisition | Other Devices and Supplies | ||
| Florian Muller | 01-Jul-2007 | Merger/Acquisition | Distributors (Healthcare) |
Ypsomed ESG
Risk Overview
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Healthcare
Industry
Rank
Percentile
Medical Supplies
Subindustry
Rank
Percentile
Ypsomed Exits (1)
Ypsomed’s most recent exit was on 13-Sep-2005 from Precimed. The exit was categorized as with 6 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Precimed | 13-Sep-2005 | Completed |
|
Ypsomed FAQs
-
When was Ypsomed founded?
Ypsomed was founded in 1984.
-
Where is Ypsomed headquartered?
Ypsomed is headquartered in Burgdorf, Switzerland.
-
What is the size of Ypsomed?
Ypsomed has 2,099 total employees.
-
What industry is Ypsomed in?
Ypsomed’s primary industry is Medical Supplies.
-
Is Ypsomed a private or public company?
Ypsomed is a Public company.
-
What is Ypsomed’s stock symbol?
The ticker symbol for Ypsomed is YPSN.
-
What is the current stock price of Ypsomed?
As of 13-Nov-2026 the stock price of Ypsomed is $514.79.
-
What is the current market cap of Ypsomed?
The current market capitalization of Ypsomed is $6.77B.
-
What is Ypsomed’s current revenue?
The trailing twelve month revenue for Ypsomed is $861M.
-
Who are Ypsomed’s competitors?
West Pharmaceutical Services, Nemera, SteriPack Group, and SHL Medical are competitors of Ypsomed.
-
What is Ypsomed’s annual earnings per share (EPS)?
Ypsomed’s EPS for 12 months was $15.84.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
